» Articles » PMID: 38595981

The Crosstalk Between Non-coding RNAs and Cell-cycle Events: A New Frontier in Cancer Therapy

Overview
Journal Mol Ther Oncol
Date 2024 Apr 10
PMID 38595981
Authors
Affiliations
Soon will be listed here.
Abstract

The cell cycle comprises sequential events during which a cell duplicates its genome and divides it into two daughter cells. This process is tightly regulated to ensure that the daughter cell receives identical copied chromosomal DNA and that any errors in the DNA during replication are correctly repaired. Cyclins and their enzyme partners, cyclin-dependent kinases (CDKs), are critical regulators of G- to M-phase transitions during the cell cycle. Mitogenic signals induce the formation of the cyclin/CDK complexes, resulting in phosphorylation and activation of the CDKs. Once activated, cyclin/CDK complexes phosphorylate specific substrates that drive the cell cycle forward. The sequential activation and inactivation of cyclin-CDK complexes are tightly controlled by activating and inactivating phosphorylation events induced by cell-cycle proteins. The non-coding RNAs (ncRNAs), which do not code for proteins, regulate cell-cycle proteins at the transcriptional and translational levels, thereby controlling their expression at different cell-cycle phases. Deregulation of ncRNAs can cause abnormal expression patterns of cell-cycle-regulating proteins, resulting in abnormalities in cell-cycle regulation and cancer development. This review explores how ncRNA dysregulation can disrupt cell division balance and discusses potential therapeutic approaches targeting these ncRNAs to control cell-cycle events in cancer treatment.

References
1.
Li X, Michels B, Tosun O, Jung J, Kappes J, Ibing S . 5'isomiR-183-5p|+2 elicits tumor suppressor activity in a negative feedback loop with E2F1. J Exp Clin Cancer Res. 2022; 41(1):190. PMC: 9161486. DOI: 10.1186/s13046-022-02380-8. View

2.
Lee E, Harris T, Tran S, Evangelista M, Arulananda S, John T . BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019; 10(5):342. PMC: 6482196. DOI: 10.1038/s41419-019-1568-3. View

3.
An J, Lv W, Zhang Y . LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017; 10:5377-5390. PMC: 5691924. DOI: 10.2147/OTT.S147586. View

4.
Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z . -Mediated Regulation of mA-Modified by mA Reader IGF2BP3 Drives ccRCC Progression. Cancer Res. 2020; 81(4):923-934. DOI: 10.1158/0008-5472.CAN-20-1619. View

5.
Attwooll C, Denchi E, Helin K . The E2F family: specific functions and overlapping interests. EMBO J. 2004; 23(24):4709-16. PMC: 535093. DOI: 10.1038/sj.emboj.7600481. View